Success Story: Overcoming RFE via Premium Processing: NIW Approval Secured for a Cancer Biology Researcher With Our Support
Client’s Testimonial:
“Thank you so much for all your help and support during this process. I really appreciate everything that your team has done.””
On September 15th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Researcher in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Graduate Researcher
State of Residence at the Time of Filing: Louisiana
Approval Notice Date: September 15th, 2026
Processing Time: 4 months, 14 days (Premium Processing Requested)
Case Summary:
A specialist in the field of cancer biology has successfully secured I-140 National Interest Waiver (NIW) approval following a Request for Evidence (RFE) under Premium Processing. The client holds an advanced degree and is currently conducting translational oncology research at a U.S. academic institution. The proposed endeavor focuses on evaluating the therapeutic efficacy, resistance mechanisms, and immune responses of cancer therapies.
This research directly addresses pressing national public health and economic priorities. Furthermore, the endeavor advances federally designated Critical and Emerging Technologies, specifically multi-omics, viral delivery systems, and predictive modeling for functional phenotypes.
To establish that the client was well positioned to advance this endeavor, the petition presented a documented record of scientific achievements, including 4 peer-reviewed journal articles (1 first-authored) and 16 conference abstracts (9 first-authored). The client’s published body of work has accrued 60 citations from independent researchers globally. Rather than presenting these raw metrics as self-evidently sufficient, our legal team provided bibliometric analysis for the USCIS adjudicator, demonstrating that two of the client’s publications ranked among the top 1% most-cited articles in clinical medicine for their respective publication years. Independent research groups have actively relied upon the client’s findings.
In response to the RFE, our team provided detailed analytical arguments and objective evidence illustrating the field-wide uptake of the client's work and its national value. USCIS approved the NIW petition, supporting the client's ongoing research to advance durable, mechanism-informed combination cancer therapies in the United States.

